Clinical trial · Interventional
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer
NCT00255489CI-TRIAL-00004348completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib | Drug | Gefitinib | ALIAS |
| palliative thoracic radiotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To characterize the safety profile of ZD 1839 in these patients
Secondary outcomes (2)
- measure
- To measure the quality of life compared to baseline
- measure
- To measure the change in disease related symptoms compared to baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent * Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2 * Histologically or cytologically conformed non-small cell lung cancer * Aged 18 or over Exclusion Criteria: * Previous thoracic radiotherapy * Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event * Known hypersensitivity to any component of study medication
References
Publications (0)
Data not yet available
No reference posted for this study.